Physician profile
Scott M Multack
NPI 1275618985
$21,394.97
in general payments reported to CMS, 2019-2025
43 companies · $719 in 2025
The $719 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,079 · 2020: $8,794 · 2021: $6,040 · 2022: $2,957 · 2023: $597 · 2024: $209 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.88 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $14,045.87 | 2019-2025 | Da Vinci Surgical System |
| Momentis Surgical INC. | $1,875.00 | 2022 | |
| Acessa Health INC. | $1,048.94 | 2021 | |
| Hologic Sales and Service, LLC | $568.85 | 2020-2025 | Acessa Provu System, Fluent Fluid Management System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Abbvie INC. | $409.48 | 2019-2023 | |
| Gynesonics, INC. | $375.01 | 2022 | |
| Avion Pharmaceuticals | $285.39 | 2019-2023 | Balcoltra |
| Pfizer INC. | $228.87 | 2019-2023 | |
| Therapeuticsmd, INC. | $198.86 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $186.74 | 2021-2025 | |
| Coopersurgical, INC. | $167.66 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Astellas Pharma US INC | $162.45 | 2023-2024 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $139.56 | 2021-2022 | |
| Exeltis, USA INC. | $139.35 | 2021-2025 | Slynd |
| Organon LLC | $124.25 | 2021-2025 | Nexplanon, Nuvaring |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $124.05 | 2021-2025 | Wegovy |
| Allergan, INC. | $102.83 | 2019-2020 | |
| Lupin INC. | $101.91 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $94.39 | 2022 | |
| Amag Pharmaceuticals, INC. | $88.82 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.90 | 2019-2022 | |
| Roche Diagnostics Corporation | $86.21 | 2019-2020 | |
| Ascend Therapeutics US, LLC | $81.33 | 2021-2023 | |
| Exact Sciences Corporation | $79.97 | 2025 | The Cologuard Plus Collection Kit |
| Myovant Sciences INC. | $71.52 | 2021-2022 | |
| Agile Therapeutics, INC. | $69.31 | 2021-2023 | Twirla |
| Evofem Biosciences, INC. | $61.40 | 2021-2022 | |
| Amgen INC. | $59.29 | 2019-2025 | Evenity, Prolia, Prolia |
| Merck Sharp & Dohme LLC | $43.31 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $39.63 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $31.26 | 2021 | |
| Sumitomo Pharma America, INC. | $26.98 | 2025 | Myfembree |
| Millicent US INC | $24.23 | 2025 | Femlyv |
| Kerecis Limited | $22.01 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Medicem INC. | $19.25 | 2021 | |
| Vertical Pharmaceuticals, LLC | $18.96 | 2019 | |
| Scynexis, INC. | $17.54 | 2022 | |
| Daiichi Sankyo INC. | $16.91 | 2019 | |
| Convatec INC. | $16.38 | 2022 | |
| Zyla Life Sciences, INC. | $14.66 | 2020 | |
| Radius Health, INC. | $13.75 | 2019 | |
| Medline Industries Lp | $12.98 | 2022 | |
| Dysis Medical, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Multack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.